Evidence map›Paper›PMID 40762799›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Predicting

Ziqing Zeng, Zizhen Zhang, Qing Xie, Jinping Tao, Wenyuan Zhou, Chunhui Yuan, Zhi Yang, Ming Lu, Jiangyuan Yu

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ziqing Zeng *Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fu-Cheng road, Haidian district, Beijing, 100142, China.
Zizhen Zhang *State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, No. 52 Fu-Cheng road, Haidian district, Beijing, 100142, China.
Qing XieKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fu-Cheng road, Haidian district, Beijing, 100142, China.
Jinping TaoKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fu-Cheng road, Haidian district, Beijing, 100142, China.
Wenyuan ZhouKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fu-Cheng road, Haidian district, Beijing, 100142, China.
Chunhui YuanDepartment of General Surgery, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, China.
Zhi YangKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fu-Cheng road, Haidian district, Beijing, 100142, China. pekyz@163.com.
Ming LuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, No. 52 Fu-Cheng road, Haidian district, Beijing, 100142, China. minglupku@126.com.
Jiangyuan YuKey laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fu-Cheng road, Haidian district, Beijing, 100142, China. yujiangyuan@aliyun.com.ORCID 0000-0002-6834-3080

Funding

Beijing Hospitals Authority's Ascent Plan No: DFL20241103National Natural Science Foundation of China projects No. 82203612, 82372001
6 · The paper itself

Abstract

backgroundThe prognosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) following metastasis is often poor. The efficacy of

methodsMultiplex immunofluorescence (mIF) staining of tumor sections was used to characterize the cellular density and spatial organization of the microenvironment of 50 NET patients. The relationship between baseline immune microenvironment and

resultsPatients with GEP-NET exhibited an immunosuppressive microenvironment. The overall response rate (ORR) to

conclusionsThe immune microenvironment parameters of GEP-NET patients are closely associated with

Indexed as

Intestinal NeoplasmsNeuroendocrine TumorsOctreotideOrganometallic CompoundsPancreatic NeoplasmsStomach NeoplasmsTumor MicroenvironmentAdultAgedFemaleHumansMaleMiddle AgedPrognosisTreatment Outcomelutetium Lu 177 dotatateOctreotideOrganometallic Compounds177Lu-DOTATATE PRRTImmune microenvironmentNeuroendocrine tumorsRadionuclide therapySpatial landscape

Identifiers

PMID40762799

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.